Financial results to be released after market
close; Conference call to be conducted at 4:30 pm ET
SARASOTA, Fla., Aug. 4, 2022
/PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a
commercial-stage fertility company focused on expanding access to
advanced treatment worldwide with its INVOcell® medical device and
the IVC procedure it enables, will report financial results for its
second quarter 2022, ended June 30,
2022, after the market close on Monday, August 15, 2022. The Company has
scheduled a conference call that same day, Monday, August 15, 2022, at 4:30 pm ET, to review the results.
Second Quarter 2022 Conference Call Details
Date and Time: Monday, August 15, 2022, at
4:30 pm ET
Call-in Information: Interested parties can access the
conference call by dialing 833-756-0861 or 412-317-5751.
Live Webcast Information: Interested parties can access
the conference call via a live webcast, which is available in the
Investor Relations section of the Company's website at
https://www.invobioscience.com/investors/
or https://app.webinar.net/LARy8Ay8DBw.
Replay: A teleconference replay of the call will be
available through August 22, 2022, at
877-344-7529 or 412-317-0088, replay access code 2909191. A webcast
replay will be available in the Investor Relations section of the
Company's website at https://www.invobioscience.com/investors/ for
90 days.
About INVO Bioscience
We are a commercial-stage fertility company dedicated to
expanding the assisted reproductive technology ("ART") marketplace
by making fertility care accessible and inclusive to people around
the world. Our flagship product is INVOcell®, a revolutionary
medical device that allows fertilization and early embryo
development to take place in vivo within the woman's body. Our
primary mission is to implement new medical technologies aimed at
increasing the availability of affordable, high-quality,
patient-centered fertility care. This treatment solution is the
world's first intravaginal culture technique for the incubation of
oocytes and sperm during fertilization and early embryo
development. This technique, designated as "IVC", provides patients
a more natural, intimate, and more affordable experience in
comparison to other ART treatments. The IVC procedure can deliver
comparable results at a fraction of the cost of traditional in
vitro fertilization ("IVF") and is a significantly more effective
treatment than intrauterine insemination ("IUI"). Our
commercialization strategy is focused on the opening of dedicated
"INVO Centers" offering the INVOcell® and IVC procedure (with three
centers in North America now
operational), in addition to continuing to sell our technology
solution into existing fertility clinics. For more information,
please visit www.invobio.com.
Safe Harbor Statement
This release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
The Company invokes the protections of the Private Securities
Litigation Reform Act of 1995. All statements regarding our
expected future financial position, results of operations, cash
flows, financing plans, business strategies, products and services,
competitive positions, growth opportunities, plans and objectives
of management for future operations, as well as statements that
include words such as "anticipate," "if," "believe," "plan,"
"estimate," "expect," "intend," "may," "could," "should," "will,"
and other similar expressions are forward-looking statements. All
forward-looking statements involve risks, uncertainties and
contingencies, many of which are beyond our control, which may
cause actual results, performance, or achievements to differ
materially from anticipated results, performance, or achievements.
Factors that may cause actual results to differ materially from
those in the forward-looking statements include those set forth in
our filings at www.sec.gov. We are under no obligation to
(and expressly disclaim any such obligation to) update or alter our
forward-looking statements, whether as a result of new information,
future events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/invo-bioscience-to-report-second-quarter-2022-financial-results-on-monday-august-15-2022-301600313.html
SOURCE INVO Bioscience, Inc.